Aescap 2.0 is an open-end fund that invests in publicly listed biotech companies. It invests in high-growth companies that develop and market new medicines and to a lesser extent diagnostics and/or medical devices. Entry into and exit from the fund is possible twice per month.
The biotech market is a large and fast-growing market where breakthrough innovations can be harnessed in a global and profitable manner. The substantial growth of the life sciences market is driven by a longer life expectancy (especially in the emerging markets) as well as an ageing population, which both are driving demand for improved and cost-effective medicine, diagnostics and medical devices.
And there is still a high unmet medical need for diseases such as Alzheimer, Arthrosis, Cancer, Diabetes, MS, Obesity, Parkinson and many other diseases including approximately 6,000 rare diseases with no treatment available at all today.
Aescap 2.0 was founded by portfolio manager Patrick Krol on March 28 2016. The fund has a focused portfolio, investing in approximately 18 companies. Within this focus it will ensure that the portfolio is diversified over different diseases and company development phases. The Fund’s objective is to make an annual net return (after deduction of costs) of 20% over the mid-term (4-5 years).
The name Aescap is derived from Aesculapius, the Roman god of medicine, and Capital.
The Portfolio Manager of Aescap 2.0 is Patrick Krol who has more than 30 years of experience in the healthcare industry. He developed an highly disciplined investment strategy based on his own experiences over decades as an investor in private as well as public medical companies.
Aescap 2.0 is managed by Privium Fund Management B.V. (Privium) as Alternative Investment Fund Manager of the Fund. Privium is an asset manager with offices in Amsterdam, London and Hong Kong which focuses on alternative investments. The Fund Manager is responsible for the entire management of the Fund in accordance with the provisions of the Fund Documents and applicable laws. The Fund Manager is also responsible for maintaining records and furnishing or causing to be furnished all required records or other information of the Fund to the extent such records, reports and other information are not maintained or furnished by the Administrator, the Legal Owner, the Depositary or other service providers. Privium Fund Management B.V. is authorized and regulated by the Dutch Authority for the Financial Markets (www.afm.nl) as an Alternative Investment Fund Manager (AIFM) as referred to in article 2:65 (a). Both Privium and the Fund are registered in the register of the AFM. Privium as a group is managing over USD 2.3 billion. For additional information on the fund manager please visit Privium´s website at: www.priviumfund.com.